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Abstract 
 
In early postmenopausal women, estrogen withdrawal is associated with increased bone turnover 
leading to bone loss and increased risk of fracture. Recent studies have suggested that the remaining 
bone tissue is significantly stronger, stiffer and has an increased tissue-level mineral content. Such 
changes may occur to compensate for bone loss or as a direct result of estrogen deficiency. To date 
many details of the physiology of osteoblastic cells during estrogen deficiency are vague. In this study 
we test the hypothesis that osteoblastic matrix mineralisation is altered at the onset of estrogen 
deficiency. In vitro cell culture experiments were carried out up to 28 days to compare the mineral 
production of MC3T3-E1 osteoblastic cells subject to estrogen deficiency (fulvestrant), enhanced 
estrogen supplementation (17-β estradiol) or a combination of both. Mineralisation was detected using 
von Kossa staining and was quantified with alizarin red absorbance readings. The expression of 
osteocalcin and osteopontin proteins, markers of osteoblast differentiation and mineralisation, was 
monitored using immunohistochemistry. Our results demonstrate that estrogen enhancement improves 
matrix mineralisation by MC3T3 cells in vitro. Furthermore this study found a significant reduction in 
the level of mineralisation when cells were treated with a combination of estrogen and fulvestrant. In 
an estrogen deficient environment mineralisation by osteoblastic cells was not altered. These findings 
suggest that altered tissue mineralisation following estrogen deficiency is not a direct result of estrogen 
deficiency on osteoblasts. Rather, we propose that altered tissue mineralisation may be a compensatory 
mechanism by bone to counter bone loss and reduced strength.  
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Introduction 
Osteoporosis is a disease, which causes bone loss, fractures and leads to severe pain, deformity and in 
certain cases secondary complications occur that result in death [1]. Postmenopausal osteoporosis 
(Type I) is the most common form of this disease and is believed to initiate when estrogen production 
is deficient following menopause [2]. During normal physiology bone is continually renewed by the 
co-ordinated activity of osteoclast and osteoblast cells [3]. However, following estrogen deficiency, 
osteoclasts remove excess bone without adequate formation by osteoblasts and this leads to significant 
bone loss [4]. Ultimately bone fractures occur under minimal trauma in the bones of the hip, wrist and 
spine.  
In early postmenopausal women and ovariectomised rats and sheep, estrogen withdrawal is associated 
with increased bone turnover resulting in a decrease in whole bone and tissue biomechanical properties 
[5-9]. Interestingly, although osteoporosis reduces bone mass and structural strength, a recent study 
found that the remaining bone tissue is significantly stronger and stiffer [10]. This unexpected finding 
has been corroborated to some extent by micro-CT studies which demonstrated an increase in the 
tissue-level mineral content which was counter to the overall reduction in bone mineral density owing 
to a loss of bone mass [10]. More recent studies have provided further evidence of an increase in tissue 
mineral during osteoporosis [11, 12]. Such changes may occur to compensate for bone loss, or 
alternatively these changes may occur prior to bone resorption and be causative. However, although it 
is intriguing to speculate on such events, it remains that the mechanisms by which an increase in 
mineralisation is initiated are unknown. 
Estrogen is instrumental in maintaining appropriate bone turnover and helping to prevent osteoporosis 
in women [13-16]. It has been well established that estrogen regulates the normal bone resorption 
process by inducing a paracrine signal in osteoblasts leading to decreased formation of mature 
osteoclasts [17] and increasing osteoclast apoptosis [18,19]. When estrogen levels are deficient the 
number of hematopoietic progenitors increases [20, 21] thereby increasing the numbers of mature 
osteoclasts forming [20-23]. One recent study suggests that the underlying basis of the protective effect 
of estrogen involves preventing osteoblast apoptosis and recruitment of osteoclasts [24]. However, 
although osteoclasts are the primary target for conventional drug treatments [25], inhibiting osteoclast 
activity alone does not completely prevent osteoporotic fractures from occurring. A greater 
understanding of estrogen and bone biology, specifically the effects of estrogen deficiency on bone 
cells, is necessary to develop successful treatments for bone metabolic disorders.  
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Osteoblasts are responsible for mineralising bone matrix by depositing mineral crystals on the organic 
matrix, which bind and nucleate in the presence of noncollagenous proteins such as alkaline 
phosphatase and osteocalcin [26,27], which are also produced by osteoblasts. Therefore tissue-level 
changes in mineral content during osteoporosis suggest that estrogen deficiency may alter the normal 
matrix mineralisation by osteoblastic cells. Indeed osteoblasts possess estrogen receptors [28] and 
studies have shown that in vitro treatment with an estrogen compound, 17ß-estradiol (E2), enhances 
proliferation and differentiation of osteoblasts [29, 30], regulates the growth of mineralised bone 
nodules and prevents apoptosis [31]. Research has shown that osteoblastic cells from osteoporotic 
patients display impaired response to mechanical stress in vitro [32]. Estrogen deficiency also induces 
osteocyte apoptosis [33, 34], which might result in hyper-mineralisation of the surrounding tissue [35-
37]. These studies indicate that a change in osteoblastic activity may occur when estrogen production is 
deficient during osteoporosis. Furthermore recent studies suggest that estrogen’s regulation of 
osteoclast activity may be a secondary effect governed by osteoblasts [38].  However to date the role of 
osteoblasts during estrogen deficiency is not fully understood and merits further research.  
Fulvestrant, or ICI 182,780, is an estrogen receptor (ER) antagonist used to treat postmenopausal 
women who are suffering from estrogen receptor-positive metastatic breast cancer. It is reported to 
have no agonist effects [39] and works both by down-regulating and by degrading the estrogen receptor 
leading to an inhibition of estrogen signalling through the estrogen receptor [40-42]. Fulvestrant is an 
analogue of estradiol which competes with endogenous estrogen for binding to the estrogen receptor 
[43] with a binding affinity that is 89% that of 17-β estradiol  [44]. Previously fulvestrant has been used 
in vitro to mimic estrogen deficiency in human osteoblasts [45], however, the exact role of fulvestrant 
on osteoblast activity is unknown. 
In this study we test the hypothesis that osteoblast number, non collagenous protein production and 
matrix mineralisation are altered at the onset of estrogen deficiency. In vitro cell culture experiments 
were carried out to compare the mineral production of osteoblastic cells subject to estrogen treatment 
and supplemented with the estrogen receptor antagonist, fulvestrant.  
 
Materials and Methods 
Cell culture 
MC3T3-E1 murine calvarial osteoblasts were maintained in α-modified MEM supplemented with 10% 
fetal bovine serum, 2mM L-glutamine and 100U/ml penicillin and 100 µg/ml streptomycin. Cells were 
grown until sub-confluence and then plated at a density of 2×104 cells per ml in 6-well plates with 2ml 
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of osteogenic media where matrix mineralisation was enhanced using 50µg/ml ascorbic acid, 10mM/L 
β-glycerophosphate and 10nM/L dexomethasome. All treatments were initiated after 24 hrs of 
incubation (day 0) when cells were cultured under separate osteogenic conditions; (1) cells were treated 
with 100nM of commercially available 17β-estradiol (E2) (Sigma), (2) cells were treated with a 
commercially available estrogen antagonist ICI 182780  (Fulvestrant, Sigma) at either 0.1 µM (F1) or 
10µM (F2), (3) to inhibit estrogen activity, cells were treated with either F1 or F2 in estrogen enhanced 
osteogenic media, (4) cells were grown in osteogenic media (control). Tissue culture mediums were 
replenished with fresh media every 3-4 days. All cells were maintained at 37 °C in a humidified 5% 
CO2 environment for a period of 7, 14, 21 or 28 days. Each experiment was performed in duplicate 
wells with 3 repeats (n=6). 
Quantification of cell number 
To determine cell number, cells were fixed in 10% neutral buffered formalin for 15 minutes before 
being rinsed twice with phosphate buffered saline (PBS). The cells were then incubated in 1 µg/ml 
DAPI diluted in PBS for 30 minutes. They were then washed and mounted using Vectashield Mounting 
Media. Slides were examined using epifluorescence microscopy and the cell number determined.  
Quantification of mineralisation 
Mineralised matrix was detected using alizarin red staining, for quantitative analysis, and von Kossa 
staining for qualitative analysis. For alizarin red staining the cells were fixed with 10% neutral buffered 
formalin for 10 minutes and then rinsed twice with deionised water before being stained with 2% 
alizarin red for 5 minutes.  For quantification, cells stained with alizarin red were de-stained with 10% 
cethylpyridium chloride for 20 minutes before 100µl of the extracted stain was transferred to a 96-well 
plate and the absorbance at 570nm was determined using an atomic absorption spectrophotometer 
(Wallac Victor, PerkinElmer Life Sciences). Using a standard curve the absorption reading was 
converted into calcium ion concentration (Ca2+) and the results were normalised to the cell number to 
estimate calcium concentration per cell.  
For von Kossa staining the cells were initially fixed in 4% paraformaldehyde for 10 minutes. They 
were treated with 5% silver nitrate for 60 minutes under bright light, followed by two washes with PBS 
and treatment with 5% sodium thiosulfate for 5 minutes. The reaction was stopped by washing the cells 
with deionised water. Cells were counter stained with nuclear fast red (Sigma) for 10 minutes before 
being rinsed in deionised water. The cells were imaged at 10X magnification under brightfield 
microscopy (Eclipse 90i, Nikon) to identify the phosphate deposits in the bone nodules.  
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Immunohistochemistry for non-collagenous protein expression 
Osteocalcin (OCN) and osteopontin (OPN) protein expression were examined by 
immunohistochemistry using primary anti-osteocalcin rabbit polyclonal IgG (antibody sc-30045, Santa 
Cruz Biotechnologies Inc, USA) and anti-osteopontin IgG rabbit polyclonal IgG (sc-20788, Santa Cruz 
Biotechnologies Inc, USA) according to the manufacturer’s instructions. Briefly, cells were fixed in 1% 
formalin for 10 minutes before being rinsed with PBS. The cells were then permeablilised with tween 
and incubated overnight at 4°C with the primary antibodies diluted at 1:200. The following day, cells 
were incubated at room temperature for 2 hours with a goat anti-rabbit IgG-FITC diluted at 1:200. The 
cells were then mounted using Vectashield mounting media (Vector Laboratories, USA). Staining was 
detected using fluorescence microscopy (Eclipse 90i, Nikon). ImageJ image processing (NIH Freeware, 
USA) was then used to determine the percentage area of the image which was stained.      
Statistics 
Results are expressed as a mean ± standard deviation. Statistical evaluations of differences between 
groups over time were carried out using multiple analyses of variance and t-tests (SPSS Inc, Chicago, 
IL). For all statistical tests, a value of p≤ 0.05 was considered to be a statistically significant difference. 
 
Results 
Cell Number: 
Results from the DAPI count showed that cell number increased significantly in the osteogenic group 
between day 0 and day 7 (p<0.005) and also between days 7 and 14 (p<0.05) (Figure 1). There was no 
subsequent increase in cell number at days 21 and 28. In the estrogen enhanced group, cell number also 
rose significantly by day 7 (p<0.005) and between days 7 and 14 (p<0.005).  As with the osteogenic 
group cell number did not significantly increase between days 14 and 21 or between days 21 and 28. A 
similar pattern was observed in F1 , F2 , F1+E2 and F2+E2 groups with a significant increase in cell 
number at day 7 (p<0.05). Cell number was again significantly greater by day 14 than day 7 (p<0.05) in 
these groups. No further increases were seen between time points in these groups. There was no 
significant difference in cell number between the groups at any of the time points. 
 
 
 
 7 
 
Alizarin Red: 
In the osteogenic group (control) the calcium concentration/cell increased significantly over time from 
day 0 to day 28 (p<0.0001) (Figure 2). Specifically, the Ca2+ concentration per cell increased 
significantly from day 0 to day 7 (p<0.0001), day 7 to 14 (p<0.0001), day 14 to day 21 (p<0.005) and 
day 21 to day 28 (p<0.0001). In the 17-β estradiol enhanced group (E2), significant increases in 
mineral production were also measured between days 0 and 28 (p<0.0001). Incrementally there was an 
increase between days 0 and 7 (p<0.001) and between days 7 and 14, 14 and 21, and days 21 and 28 
(p<0.0001). In the group treated with the lower fulvestrant concentration (F1) it was found that 
mineralisation also increased significantly from day 0 to day 28 (p<0.0001). There were significant 
incremental increases in mineralisation between days 0 and 7, days 7 and 14, and days 21 and 28 
(p<0.0001). At the higher fulvestrant concentration, F2, there was again a significant increase in 
mineralisation between days 0 and 28 and also between each time point (p<0.0001). 
MC3T3s which were cultured with estrogen plus fulvestrant (F1+E2 and F2+E2) also showed an 
increase in mineral production by day 28 relative to day 0 (p<0.0001). In F1+E2 mineralisation 
increased significantly between days 0 and 7 (p<0.0001), day 7 and 14 (p<0.0001) and days 21 and 28 
(p<0.0001). However there was no increase in mineralisation between days 14 and 21 (p=0.3). In 
MC3T3 cells cultured with F2+E2 again a significant increase in mineralisation over the duration of the 
study was found (p<0.0001). With significant increases measured during each interval, between days 0 
and 7 (p<0.0001), days 7 to 14 (p<0.0005), days 14 and 21 (p<0.005) and between days 21 and 28 
(p<0.0001).  
Comparison between the groups at each time point found that at day 7 there was no significant 
difference in the level of mineralisation between the groups. By day 14, mineralisation was 
significantly greater in the estrogen enhanced group and also in the lower fulvestrant concentration, F1, 
than the osteogenic group (p<0.001). At day 21, mineralisation continued to be significantly greater in 
E2 than in the osteogenic group (p<0.0001). At day 21 mineralisation was also significantly lower in 
F1+E2 than in the osteogenic group (p<0.0001). By the final time point, day 28, mineralisation 
continued to be greater in E2 than the osteogenic group (p<0.0001). There was no significant difference 
in mineralisation between either F1 or F2 and the osteogenic control. Notably, at this point 
mineralisation was significantly less in F1+E2 and F2+E2, than in the osteogenic group (p<0.0001).  
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Von Kossa staining: 
The Von Kossa staining supports the results from the alizarin red quantification. The level of 
mineralisation, as indicated by mineralised nodules in Figure 3, increases over time with the largest 
number of mineralised nodules evident at day 28 in all conditions. A greater number of nodules are 
visible in the E2 group than any other group. The least number of nodules are present in the MC3T3-E1 
samples which were cultured with estrogen plus fulvestrant.  
 
Osteocalcin and Osteopontin: 
Osteocalcin expression and osteopontin expression were reported as the % area of fluorescence. Figure 
4a shows that osteocalcin expression did not increase significantly between days 0 and 7 or days 7 and 
14 in any of the groups. There was also no increase between days 14 and 21 in any of the groups with 
the exception of E2 (p<0.05). However, between days 21 and 28 there was a significant increase 
(p<0.0001) in all groups. In the estrogen plus fulvestrant groups, osteocalcin expression did not 
significantly change between days 0 and 7, however, between days 7 and 14 there was a significant 
reduction in expression (p<0.05). No change in expression was measured between day 14 and day 21, 
and again there was a significant increase between days 21 and 28 (p<0.0001).   
At day 7 there were no significant changes in osteocalcin expression in any of the experimental groups 
relative to control. At day 14, expression in F1+E2 was significantly reduced relative to the control 
group (p<0.05). By day 21, osteocalcin expression in F1+E2 and F2+E2 and also in F2 was significantly 
reduced relative to the control group (p<0.001). However, expression was significantly higher in the 
estrogen enhanced group than the controls (p<0.05). At day 28, osteocalcin expression was again 
significantly reduced in F1+E2 and F2+E2 (p<0.0001) and also in F1 (p<0.05) while expression 
remained highest in the estrogen enhanced group (p<0.001). 
Osteopontin expression did not significantly increase between days 0 and 7 in any of the experimental 
conditions (Figure 4b). There was a significant increase in expression in all groups between days 7 and 
14 (p<0.05), days 14 and 21 (p<0.001) and also between days 21 and 28 (p<0.001). No significant 
difference in expression was measured between groups at days 7 or 14. At day 21, osteopontin 
expression was significantly greater in the estrogen enhanced group than the control group (p<0.05). 
Meanwhile in F1+E2 and F2+E2, there was a significantly lower osteopontin expression than the 
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controls (p<0.001). At day 28 E2 remained significantly higher and F1+E2 and F2+E2 were 
significantly less, as was the case with F1 (p<0.05).  
DISCUSSION 
In this study we report that estrogen treatment alone increases matrix mineralisation by MC3T3 cells in 
vitro, while blocking the estrogen receptors through the use of fulvestrant alone did not influence 
mineralisation by these osteoblastic cells. Interestingly, culturing cells in estrogen plus fulvestrant 
significantly reduced mineralisation by MC3T3 cells. Osteocalcin protein expression corroborated the 
mineralisation results while osteopontin expression also highlighted the differentiation of osteoblasts. 
DAPI staining showed that there was no significant difference in cell number between the groups at 
any of the time points. Thus, changes in protein expression and mineral levels between the groups can 
be attributed to changes in the ability of the osteoblasts to produce mineral rather than due to changes 
in the number of cells present.  
The current study has a number of limitations. It may not be correct to assume that fulvestrant 
treatment accurately represents in vivo estrogen deficiency as the cells were not previously treated with 
high levels of estrogen prior to treatment with fulvestrant. Nonetheless the current studies provide an 
insight into bone cell biology in an estrogen deficienct environment. Another limitation of this study 
may be the use of MC3T3 cells, a murine immortalised cell line, to infer estrogen related changes in 
human bone cells. MC3T3-E1 cells are an osteoblast cell line which express high amounts of alkaline 
phosphatase, produce mineral and terminally differentiate into osteocytes [46] , and for these reasons 
are accepted as an appropriate model of primary osteoblasts when cultured with osteogenic media 
[47,48]  . Finally, it was not possible to test the hypothesis that increased mineralisation occurs as a 
compensatory mechanism by bone to counter bone loss following estrogen deficiency using in vitro 
cell culture experiments. Future studies are required that employ an in vivo model to test this 
hypothesis and fully understand the origin of changes in bone tissue mineralisation during estrogen 
deficiency.   
 The control cells behaved consistently with previous studies whereby the osteoblastic cells proliferated 
rapidly up until day 14 after which there was a period of extracellular matrix development up until day 
21, production of OCN and OPN, followed by a period of mineralisation [49]. Cells treated with 
estrogen increased in number rapidly and produced significantly more mineral, osteocalcin and 
osteopontin than any other group.  Studies have suggested that estrogens have an anabolic effect that 
directly influences osteoblasts [50,51]. The current study supports this as the increased osteopontin 
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expression seen at day 21 is a characteristic marker of osteoblast differentiation [49].  Estrogen also up-
regulates the mRNA expression of osteogenic genes for alkaline phosphatase, collagen I, transforming 
growth factor-beta1 and bone morphogenic protein-2 [52].  In this study we also show that estrogen 
increased osteocalcin expression and mineralisation.  
The current study found that treatment with fulvestrant alone at either 0.1µM or 10µM did not result in 
significant changes in cell number or mineralisation when compared to the control group. One previous 
study also showed that addition of fulvestrant to osteoblasts did not cause any change in cell 
proliferation, osteoblastic markers or mineralisation when compared to control cultures [29]. Although 
mineralisation was not significantly different between the fulvestrant treated groups and the controls, 
both osteocalcin and osteopontin expression were significantly reduced in F1 at day 28. It has 
previously been shown that fulvestrant can reduce bone volume in rats [53] and treatment of human 
osteoblasts with fulvestrant in non-osteogenic conditions results in downregulation of estrogen receptor 
expression and can induce adipogenesis [45]. The results from the current study suggest that 
attachment of the fulvestrant molecule, an estrogen antagonist, to the osteoblast estrogen receptor is not 
sufficient to initiate an increase in mineralisation. As the cells were expanded and cultured in alpha 
MEM which contains phenol red, a weak estrogen [54], blocking the estrogen receptors with 
fulvestrant is depriving the cells of estrogen. These findings therefore suggest that estrogen deficiency 
might not directly alter the normal mineralisation process by osteoblastic cells.  
Therefore tissue level changes in mineral content in osteoporotic bone might arise to compensate for 
bone loss i.e. changes in mineralisation occur indirectly as a result of structural changes in the bone 
rather than as a direct result of estrogen deficiency. It is known that osteoblasts and osteocytes can 
transduce mechanical signals into biochemical stimuli to alter bone mass [26,55]. Following 
osteoporotic bone loss these cells are likely to be subjected to elevated loading. Therefore, it may be 
that the mechanical properties of remaining tissue are altered to compensate for the overall reduction in 
bone strength to some extent, perhaps when osteocytes embedded in the remaining tissue experience 
elevated loading.  
When cells were grown with both estrogen and fulvestrant there was a significant decrease in the 
amount of mineral produced by the osteoblasts in comparison to those treated in osteogenic media and 
with either estrogen or fulvestrant alone. That mineralisation was significantly less than the control 
group is interesting. Although selective-estrogen receptor downregulators, such as fulvestrant, are 
reported to lack estrogen agonist activity, results of preclinical studies have shown that fulvestrant may 
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actually have agonist and antagonist effects on bone, depending on the presence of circulating estradiol 
levels [58]. In ovariectomized rats, bone turnover and bone loss increased after fulvestrant therapy, 
whereas bone turnover and bone loss decreased in rats with intact ovaries receiving fulvestrant [53]. In 
the current study it would appear that in the absence of estrogen, fulvestrant has no effect on osteoblast 
activity whereas in the presence of estrogen, osteoblast activity is decreased.  The reasons for this are 
not entirely clear. Until very recently no human data existed regarding fulvestrant's effect on bone 
turnover. Unlike other breast cancer treatments, such as tamoxifen which possess some agonist effects, 
fulvestrant is reported to have none [59]. However, a pilot study of 14 postmenopausal women 
suffering from breast cancer found that bone formation and resorption increased over time following 
treatment with fulvestrant [60]. As mentioned previously the decline in estrogen levels following 
menopause results in increased bone turnover which leads to decreased bone mass and an increased 
risk of fracture. From the current study it appears that osteoblast activity is inhibited by the presence of 
estrogen and fulvestrant in combination. In conjunction with previous studies (52,56,58) which indicate 
that the effects of fulvestrant may depend on the levels of circulating hormones and also that fulvestrant 
may have some agonist effects with respect to bone, this study suggests that there is much to learn 
about the effects of fulvestrant on bone cells. Certainly the current findings suggest that in the presence 
of estrogen, fulvestrant has a deleterious effect on bone formation.  
Conclusion 
This study has found that estrogen deficiency, as induced by fulvestrant, had no significant effect on 
mineralisation by the osteoblasts. This result suggests that the increased mineralisation seen in previous 
studies following estrogen deficiency is not a direct result of estrogen deficiency on the osteoblasts. 
Rather, it is hypothesised that it may occur as a compensatory mechanism by bone to counter the loss 
of bone mass following estrogen deficiency.   
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Figure 1: Cell number measured using DAPI showed a significant increase between day 0 and day 28 
in all groups (A, p<0.001). All groups showed a significant increase in cell number between days 0 and 
7 and days 7 and 14. There was no significant difference in cell number between the groups at any time 
point.   
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Figure 2: Analysis of cell’s ability to produce mineral showed an increase over time in all groups with 
significantly more mineral by day 28 (C, p<0.0001) regardless of the conditions. Notable increases in 
mineral production were in the estrogen enhanced group at day 14 (A, p<0.001) and days 21 and 28 (B, 
p<0.0001). Mineral production was also significantly increased in F1 at Day 14 (p<0.001). Significant 
reductions in mineral were seen at days 21 and 28 in F1+E2 and by day 28 in F2+E2 (B, p<0.0001). 
 
 
 
Figure 3: von Kossa and nuclear fast red stained MC3T3 cells (4X magnification; scale bar = 100µm) 
cultured for 7,14, 21 and 28 days in various media conditions. An increase in cell number can be seen 
in all groups over time and increased mineralisation over time in the osteogenic and estrogen enriched 
groups is evident.  
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Figure 4: Osteocalcin expression was significantly increased in all groups by day 28 (D, p<0.0001). At 
day 14 expression in F1+E2 was significantly reduced (A, p<0.05). By day 21 osteocalcin expression 
was significantly lower in F1+E2, F2+E2 and in F2 (B, p<0.001) and remained higher in E2 (A, p<0.05). 
At the final time point, expression continued to be significantly greater in E2 (B, p<0.001).  
Osteopontin expression was significantly increased in all groups by days 21 and day 28 (A, p<0.0001). 
At day 21 expression levels were significantly lower in F1+E2 and F2+E2 (B, p<0.001) and were 
higher in E2 (C, p<0.05). At the final time point osteopontin expression continued to be significantly 
higher in E2 (C, p<0.05) while expression remained lower in F1+E2 and F2+E2 (B, p<0.001) and a 
decrease in F1 (C, p<0.05) was seen.  
 
